BACARDI
12.9.2022 13:01:51 CEST | Business Wire | Press release
Bacardi announces a change at the top of its global travel retail business (GTR), effective January 2023. The current Managing Director, Vinay Golikeri, moves out of global travel retail to take on the role of Managing Director, India, and Neighboring Countries, handing over the reins to Leila Stansfield. Leila is an experienced global travel retail veteran, having previously held roles as GTR Finance Director and GTR Marketing Director. She will be the first female lead for the division. She is currently On-Trade Sales Director, Bacardi UK & Ireland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005141/en/
Leila Stansfield to lead Bacardi global travel retail business (GTR), effective January 2023. (Photo: Business Wire)
Vijay Subramaniam, Regional President AMEA & GTR, Bacardi comments on the change, “Vinay has played a pivotal role in leading and developing our global travel retail business. The last few years have been particularly difficult for this channel, and Vinay has successfully navigated the challenges of the pandemic. He has spearheaded our ambitions as a front-runner in the omnichannel revolution sweeping travel retail by partnering with retail customers, introducing significant innovation in shopper experience and our brand portfolio. I would like to thank Vinay for his unwavering drive and positive leadership and to wish him every success in his new role.
“Meanwhile, we are delighted to welcome Leila Stansfield back to GTR. She is a driving force in our senior leadership team and brings valuable commercial acumen from across several aspects of our business. This is a time of transformational opportunity for global travel retail and Bacardi is deeply committed for the long term. With a passion for people – our customers, consumers and for unlocking potential in her team - Leila will be a tremendous leader to move GTR into the new omnichannel era, maximizing the unrivaled dynamics in terms of strategic brand-building and commercial opportunity as well as driving our ESG goals – a key objective in our strategic ambitions for global travel retail.”
Commenting on his time in Bacardi GTR, Vinay Golikeri said, “It’s been such a privilege to lead the Bacardi global travel retail business, and I would especially like to call out the most magnificent team of talented people I’ve worked with and to thank them for their fearless commitment and passion. These individuals have delivered phenomenal work in the toughest of times, enabling us to reinvent our business in global travel retail and to emerge stronger with new possibilities, notably in forging omnichannel solutions that are the bedrock of the new era in this remarkable market.”
Looking ahead to her new role, Leila Stansfield adds, “I am very excited to be returning to global travel retail in January 2023, especially at a time when the market looks set to move towards full recovery. I look forward to reconnecting with our retail partners and stakeholders to accelerate and deliver mutually beneficial strategies for growth.”
NOTES TO EDITORS
About BACARDI GLOBAL TRAVEL RETAIL
The Bacardi Global Travel Retail Division is a stand-alone business unit of Bacardi Limited. Through Bacardi’s portfolio of premium and super-premium brands, including BACARDÍ® rum, GREY GOOSE® vodka, DEWAR’S® blended Scotch whisky, BOMBAY SAPPHIRE® gin, PATRÓN® tequila, MARTINI® vermouth and sparkling wine, SAINT GERMAIN® liqueur, BARON OTARD® cognac, BÉNÉDICTINE® liqueur, and 42BELOW® vodka, the Bacardi Global Travel Retail Division creates unique and innovative experiences for travelers.
The brands noted above are part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Drink Responsibly
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005141/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
